Empresa RXi Pharmaceuticals Corp Nasdaq
Acciones
US74979C3034
Biotecnología e investigación médica
Precio de cierre
Otros sitios de cotización
|
||
- USD | - |
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/06/12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15/09/17 |
Linda M. Mahoney
PRN | Corporate Officer/Principal | - | 10/11/22 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/06/12 |
Director/Board Member | 73 | 02/05/22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18/04/13 |
Jonathan Freeman
BRD | Director/Board Member | 56 | 07/06/17 |
Robert Ferrara
BRD | Director/Board Member | 73 | 01/10/19 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 4 591 700 | 4 564 638 ( 99,41 %) | 0 | 99,41 % |
Información de la empresa
Phio Pharmaceuticals Corp.
11 Apex Drive Suite 300A PMB 2006
01752, Marlborough
+508-767-3861
http://www.phiopharma.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
+27,66 % | 49,18 mil M | |
+0,94 % | 42,11 mil M | |
+50,41 % | 40,37 mil M | |
-5,26 % | 28,85 mil M | |
+13,23 % | 26,09 mil M | |
-21,79 % | 18,71 mil M | |
+10,19 % | 13,26 mil M | |
+31,87 % | 12,32 mil M | |
+0,03 % | 11,99 mil M |
- Bolsa de valores
- Acciones
- Acción PHIO
- Acción
- Empresa RXi Pharmaceuticals Corp